Abstract
Background: Ustekinumab (UST) demonstrates greater real-world adherence/persistence for psoriasis (PsO) within 1 year after initiation than adalimumab (ADA), apremilast (APR), etanercept (ETA), and secukinumab (SEC). Short-term discontinuation rates remain unclear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
